Twin and family-based studies indicate that genetic factors might be involved in the risk of transient ischemic attack (TIA) and ischemic stroke (IS). Identification of genetic risk factors for new vascular events after cerebral ischemia may target secondary prevention. The overall aim of POLARIS is to study which polymorphisms predispose to new vascular events after TIA/IS and to assess their predictive value. Patients who have had a TIA or IS of presumed arterial origin are included. The study design is twofold. In part one the prevalences of polymorphisms will be compared between 300 long-term survivors of the Dutch TIA Trial (average follow-up 10 years) and 820 patients with recent TIA/IS. In part two a cohort of 820 patients with recent TIA/IS will be followed for the occurrence of vascular events for an average of 3.5 years. Several polymorphisms of interest will be genotyped, including factor V Leiden, prothrombin 20210A, 5,10-methylenetetrahydrofolate reductase, HR2 haplotype factor V and factor XIII Val34Leu.

Dippel DW, Koudstaal PJ: We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group. Stroke 1997;28:774–776.
Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD: A study of twins and stroke. Stroke 1992;23:221–223.
Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH: Familial aggregation of stroke. The Framingham Study. Stroke 1993;24:1366–1371.
Tanne D, Yaari S, Goldbourt U: Risk profile and prediction of long-term ischemic stroke mortality: A 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. Circulation 1998;98:1365–1371.
Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CD: Ethnic differences in incidence of stroke: Prospective study with stroke register. BMJ 1999;318:967–971.
Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, Mas JL, Cabanis EA, Baudrimont M, Maciazek J: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993;3:256–259.
Hassan A, Markus HS: Genetics and ischaemic stroke. Brain 2000;123:1784–1812.
Boerwinkle E, Doris PA, Fornage M: Field of needs: The genetics of stroke. Circulation 1999;99:331–333.
Elbaz A, Amarenco P: Genetic susceptibility and ischaemic stroke. Curr Opin Neurol 1999;12:47–55.
Bird TD, Jarvik GP, Wood NW: Genetic association studies: Genes in search of diseases. Neurology 2001;57:1153–1154.
Cardon LR, Bell JI: Association study designs for complex diseases. Nat Rev Genet 2001;2:91–99.
Hegele RA: SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol 2002;22:1058–1061.
The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261–1266.
van Wijk, I. and Algra A: LiLAC – Life Long After Cerebral ischemia. Preliminary results on long-term (>10 year) survival in patients with cerebral ischaemia of arterial origin. Cerebrovasc Dis 2003;16(suppl 4):3.
Bonafe M, Marchegiani F, Cardelli M, Olivieri F, Cavallone L, Giovagnetti S, Pieri C, Marra M, Antonicelli R, Troiano L, Gueresi P, Passeri G, Berardelli M, Paolisso G, Barbieri M, Tesei S, Lisa R, De Benedictis G, Franceschi C: Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet 2002;10:292–296.
Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y: Second manifestations of ARTerial disease (SMART) study: Rationale and design. Eur J Epidemiol. 1999;15:773–781.
De Schryver EL: Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebrovasc Dis 2000;10:147–150.
World Medical Association Declaration of Helsinki: 2000.
Meschia JF: Addressing the heterogeneity of the ischemic stroke phenotype in human genetics research. Stroke 2002;33:2770–2774.
Wu AH, Tsongalis GJ: Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001;87:1361–1366.
Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG: Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002;100:3–10.
Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L: Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol 2002;249:1391–1397.
Gerdes VE, ten Cate H, de Groot E, Kwa VI, Prins MH, Reitsma PH, Buller HR, Brandjes DP: Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. Atherosclerosis 2002;163:135–140.
Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. The Homocystein Studies Collaboration. JAMA 2002;288:2015–2022.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113.
Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL: Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: Results of a meta-analysis. Neurology 2002;59:529–536.
Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002;325:1202.
Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P: The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000;95:586–591.
Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS: Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol. 2002;116:376–382.
Margaglione M, Bossone A, Coalizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, Di MG: FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 2002;87:32–36.
Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De S, V, Castaman G, Finazzi G, Mannucci PM: Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999;94:3062–3066.
de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM: The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000;83:577–582.
Doggen CJ, de Visser MC, Vos HL, Bertina RM, Cats VM, Rosendaal FR: The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000;84:815–818.
Austin H, Chimowitz MI, Hill HA, Chaturvedi S, Wechsler LR, Wityk RJ, Walz E, Wilterdink JL, Coull B, Sila CA, Mitsias P, Evatt B, Hooper WC: Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke 2002;33:2762–2768.
Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35–41.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
Taioli E, Garte S: Covariates and confounding in epidemiologic studies using metabolic gene polymorphisms. Int J Cancer 2002;100:97–100.
Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A: Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003;107:17–20.
Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG: Combined carrier status of prothrombin 20210A and factor XIII-A L34 alleles as a strong risk factor for myocardial infarction: Evidence of a gene-gene interaction. Blood 2003;101:3037–3041.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.